Conservative commentator Charlie Kirk shot and killed at Utah event
Kestra Medical Technologies, Ltd. (NASDAQ:KMTS), a medical technology company with a market capitalization of $828 million and currently rated ’FAIR’ on InvestingPro’s Financial Health Score, reported the results of its 2025 annual general meeting of shareholders, held Wednesday, according to a press release statement based on a recent SEC filing.
Approximately 95% of the company’s outstanding common shares were represented at the meeting, with 48,835,102 shares voted out of 51,348,656 eligible as of the July 7, 2025, record date.
Shareholders elected two Class I directors, Conor Hanley and Elizabeth Kwo, to serve until the 2028 annual meeting. Hanley received 43,121,331 votes in favor, 3,640,519 against, and 14,870 abstentions. Kwo received 43,118,417 votes in favor, 3,643,439 against, and 14,864 abstentions.
The appointment of PricewaterhouseCoopers as the company’s independent registered public accounting firm for the fiscal year ending April 30, 2026, was ratified, with 48,814,793 votes in favor, 5,444 against, and 14,865 abstentions.
Shareholders also approved the Kestra Medical Technologies , Ltd. 2025 Employee Stock Purchase Plan. The proposal received 45,801,106 votes in favor, 975,504 against, and 110 abstentions.
All information is based on the company’s press release statement and SEC filing.
In other recent news, Kestra Medical Technologies reported strong fiscal fourth-quarter results for 2025, with a total revenue of $17.2 million, marking a 71% year-over-year growth. This performance surpassed both Stifel and consensus estimates of $15.7 million, driven by a 43% increase in ASSURE prescription volume and enhancements in revenue cycle management. Despite a negative earnings per share of -2.21, analysts from Piper Sandler reiterated an Overweight rating with a price target of $27.00, while Stifel maintained a Buy rating with a $28.00 price target, highlighting the strong earnings.
In other developments, Biobeat Technologies appointed Raymond W. Cohen as Chairman of its Board of Directors. Cohen, with over 40 years in the life sciences industry, has a history of leading successful acquisitions, including the sale of Axonics, Inc. to Boston Scientific for $3.7 billion. Additionally, InspireMD announced the appointment of Cohen to its Board of Directors, leveraging his extensive experience in medical technology. These appointments reflect the companies’ strategic moves to strengthen their leadership teams with seasoned industry veterans.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.